Association between Smoking Status and Incident Non-Cystic Fibrosis Bronchiectasis in Young Adults: A Nationwide Population-Based Study
- PMID: 35629114
- PMCID: PMC9144886
- DOI: 10.3390/jpm12050691
Association between Smoking Status and Incident Non-Cystic Fibrosis Bronchiectasis in Young Adults: A Nationwide Population-Based Study
Abstract
Smoking traditionally has not been considered as a cause of bronchiectasis. However, few studies have evaluated the association between smoking and bronchiectasis. This study aimed to investigate the association between smoking status and bronchiectasis development in young adults. This study included 6,861,282 adults aged 20−39 years from the Korean National Health Insurance Service database 2009−2012 who were followed-up until the date of development of bronchiectasis, death, or 31 December 2018. We evaluated the incidence of bronchiectasis according to smoking status. During a mean of 7.4 years of follow-up, 23,609 (0.3%) participants developed bronchiectasis. In multivariable Cox regression analysis, ex-smokers (adjusted hazard ratio (aHR) = 1.07, 95% confidence interval (CI) = 1.03−1.13) and current-smokers (aHR = 1.06, 95% CI = 1.02−1.10) were associated with incident bronchiectasis, with the highest HR in ≥ 10 pack-years current smokers (aHR = 1.12, 95% CI = 1.06−1.16). The association of smoking with bronchiectasis was more profound in females than in males (p for interaction < 0.001), in younger than in older participants (p for interaction = 0.036), and in the overweight and obese than in the normal weight or underweight (p for interaction = 0.023). In conclusion, our study shows that smoking is associated with incident bronchiectasis in young adults. The association of smoking with bronchiectasis development was stronger in females, 20−29 year-olds, and the overweight and obese than in males, 30−40-year-olds, and the normal weight or underweight, respectively.
Keywords: bronchiectasis; epidemiology; risk factor; smoking.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Being Underweight Increases the Risk of Non-Cystic Fibrosis Bronchiectasis in the Young Population: A Nationwide Population-Based Study.Nutrients. 2021 Sep 15;13(9):3206. doi: 10.3390/nu13093206. Nutrients. 2021. PMID: 34579084 Free PMC article.
-
Risk Factors of Incident Lung Cancer in Patients with Non-Cystic Fibrosis Bronchiectasis: A Korean Population-Based Study.Cancers (Basel). 2022 May 25;14(11):2604. doi: 10.3390/cancers14112604. Cancers (Basel). 2022. PMID: 35681584 Free PMC article.
-
Non-Cystic Fibrosis Bronchiectasis Increases the Risk of Lung Cancer Independent of Smoking Status.Ann Am Thorac Soc. 2022 Sep;19(9):1551-1560. doi: 10.1513/AnnalsATS.202111-1257OC. Ann Am Thorac Soc. 2022. PMID: 35533306 Free PMC article.
-
[Body mass index and cancer incidence:a prospective cohort study in northern China].Zhonghua Liu Xing Bing Xue Za Zhi. 2014 Mar;35(3):231-6. Zhonghua Liu Xing Bing Xue Za Zhi. 2014. PMID: 24831616 Chinese.
-
Association between non-cystic fibrosis bronchiectasis and the risk of incident dementia: A nationwide cohort study.Chron Respir Dis. 2023 Jan-Dec;20:14799731231222282. doi: 10.1177/14799731231222282. Chron Respir Dis. 2023. PMID: 38100725 Free PMC article.
Cited by
-
Immediately scheduled for an appointment to smoking cessation clinics: Key to quitting smoking in chronic airway disease - a multicenter randomized study.Tob Induc Dis. 2025 Jun 5;23. doi: 10.18332/tid/204254. eCollection 2025. Tob Induc Dis. 2025. PMID: 40475312 Free PMC article.
-
Chronic obstructive pulmonary disease is a risk factor for non-tuberculous mycobacterial pulmonary disease: a population-based matched cohort study.BMJ Open Respir Res. 2025 Jun 20;12(1):e002373. doi: 10.1136/bmjresp-2024-002373. BMJ Open Respir Res. 2025. PMID: 40541276 Free PMC article.
-
Risk of acute exacerbation of chronic obstructive pulmonary disease after COVID-19 recovery: a nationwide population-based cohort study.Respir Res. 2025 Mar 27;26(1):116. doi: 10.1186/s12931-025-03123-x. Respir Res. 2025. PMID: 40148876 Free PMC article.
-
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.ERJ Open Res. 2024 Jul 22;10(4):00151-2024. doi: 10.1183/23120541.00151-2024. eCollection 2024 Jul. ERJ Open Res. 2024. PMID: 39040578 Free PMC article.
-
Baseline neutrophil-to-lymphocyte ratio as a predictor of response to hospitalized bronchiectasis exacerbation risks.Eur Clin Respir J. 2024 Jun 27;11(1):2372901. doi: 10.1080/20018525.2024.2372901. eCollection 2024. Eur Clin Respir J. 2024. PMID: 38946716 Free PMC article.
References
-
- Quint J.K., Millett E.R., Joshi M., Navaratnam V., Thomas S.L., Hurst J.R., Smeeth L., Brown J.S. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur. Respir. J. 2016;47:186–193. doi: 10.1183/13993003.01033-2015. - DOI - PMC - PubMed
-
- Yang B., Choi H., Lim J.H., Park H.Y., Kang D., Cho J., Lee J.S., Lee S.W., Oh Y.M., Moon J.Y., et al. The disease burden of bronchiectasis in comparison with chronic obstructive pulmonary disease: A national database study in Korea. Ann. Transl. Med. 2019;7:770. doi: 10.21037/atm.2019.11.55. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources